1. Introduction {#sec0005}
===============

The advent of prostate-specific antigen (PSA) screening has led to stage, grade, and risk migration towards diagnosis of less aggressive prostate cancer (PCa). As a result, men with localised PCa and physicians who advise them face a difficult therapeutic dilemma: surveillance versus radical whole-gland therapy. The available evidence from randomised controlled trials (RCTs) demonstrates that there is little to no difference between these choices in terms of overall and cancer-specific survival after a median of 10 yr of follow-up [@bib0005]. In light of these findings, the patient\'s dilemma is made that much more profound by the significant rates of genitourinary and rectal side effects, which can occur despite technological improvements in surgery and radiation [@bib0010; @bib0015; @bib0020; @bib0025].

Consequently, there has been interest in focal therapy. This tissue-preserving strategy has at its core the reduction of treatment-related toxicity by minimising damage caused to the prostate and adjacent structures while attempting to retain the benefits of treating cancer [@bib0030; @bib0035; @bib0040; @bib0045]. This is an approach adapted by many other solid-organ malignancies, including renal, thyroid, breast, liver, and pancreas, but in which PCa has limited evidence and acceptance. Indeed, since whole-mount analysis of radical prostatectomy specimens has shown the presence of multiple foci of disease in most cases, the perception has been that whole-gland therapies are mandatory. However, new evidence suggests that the natural history of the disease is predominantly driven by the largest lesion with the highest grade, the so-called index lesion [@bib0050]. Therefore, targeted treatment delivered to the index lesion while sparing the rest of the gland may be a rational approach in men with intermediate- and low-volume, high-risk PCa that has disease suitable for a focal tissue-preserving approach. This proposition could make focal therapy achievable in the majority of men with localised PCa.

At the moment, any approach able to preserve part of the prostatic tissue (eg, "hockey stick" ablation, hemiablation, and focal ablation) is considered *focal therapy*. Many groups have published limited data on outcomes following focal therapy, and many others are actively engaged or considering prospective comparative effectiveness research in this area. It is an opportune time for a systematic review to evaluate the current evidence base and identify strengths and weaknesses and points of uncertainty about focal therapy to guide future trials.

2. Evidence acquisition {#sec0010}
=======================

This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We limited our systematic search to studies reporting on actual focal-therapy outcomes. We report on the following specific categories of data from the identified literature: (1) definition of the ideal candidate for focal therapy, (2) disease localisation, (3) identification of which lesions to target, (4) definitions of success and failure in focal therapy, and (5) morbidity and cancer-control outcomes after focal therapy.

Studies were identified by electronic search of Medline (through PubMed), Embase, Web of Science, and Cochrane Review databases from inception of the each respective database through 31 October 2012, with prespecified English language and human-studies restrictions. In addition, registered trials were retrieved from trials registries (ClinicalTrials.gov and the International Standard Randomised Controlled Trial Number). We conducted a search of ongoing trials to allow us to determine the current thinking on patient eligibility, disease localisation, and types of outcome measures that investigators in this area are currently using. The search strategy was as follows: "PCa" OR "prostatic neoplasms" AND "focal treatment" OR "focal therapy" OR "tissue-preserving/-preservation" OR "subtotal" OR "cryosurgery" OR "cryotherapy" OR "cryoablation" OR "high-intensity focused ultrasound ablation" OR "HIFU" OR "photodynamic therapy" OR "PDT" OR "laser therapy" OR "brachytherapy."

RCTs, prospective development studies, and retrospective case series investigating ablative techniques to treat biopsy-proven PCa in a subtotal manner in the primary or salvage setting were included. Eligibility was reviewed separately by two reporters (M.V. and H.U.A.). In case of disagreement despite further discussion between the two authors, the senior author (T.J.P.) arbitrated. All selected articles were fully reviewed, and data extraction was predefined pro forma. Authors of included studies were contacted when one of the outcomes was not clearly or explicitly reported or when there were concerns about duplicate data sets; one reminder was sent for nonreplies. In cases where no reply was received, we chose not to report uncertain outcomes. When two or more series completely overlapped in time, only the largest series was reported; when the overlapping was partial over a limited time, all studies were reported, and the possible duplication of data was highlighted in the tables.

The primary end point was treatment-related side effects. We defined these in the following manner and differentiated them based on those reported by physicians and those using validated patient-reported questionnaires: leak-free continence, leak-free and pad-free continence, erections sufficient for penetration, and rectal toxicity (diarrhoea, bleeding, pain, rectourethral fistula). Functional outcomes were extracted from each study only when preoperative and postoperative data were available. In other words, only patients with normal function before treatment were considered. For instance, when calculating erectile function outcome, the denominator was represented by the men potent before the operation. Secondary end points were failure defined by residual PCa in the treatment area proven by biopsy, overall complications, quality of life (QOL) outcomes, need for secondary local or systemic treatment, and mortality. Biochemical outcomes also were reported.

The following data were extracted from each study:•Predefined eligibility criteria•Participants, including sample size, age, D'Amico or National Comprehensive Cancer Network cancer Risk classification, PSA level, and Gleason grade•Preoperative diagnostic tools, such as imaging and biopsy techniques used to localise disease•Type of intervention, including ablation modality, type of focal therapy, type of anaesthesia, and length of hospital stay•Follow-up duration•Toxicity•Cancer-control measures, including histology (divided into *for cause* and *protocol* biopsy based on whether biopsies were conducted on suspicion of failure or whether the protocol required biopsies in all men, respectively) and biochemical disease-free survival (using current, nonvalidated definitions)•PSA kinetics•Need for additional treatments•Metastatic disease•Mortality.

Trifecta outcomes (pad-free continence, erections sufficient for penetration with or without oral phosphodiesterase type 5 inhibitors \[PDE5-Is\], and disease control at last follow-up) were extracted where possible.

The design of each study was reported according to the Idea Development Evaluation Assessment and Long-term (IDEAL) recommendations for evaluation of surgical innovations, proposed by the Balliol Collaboration and based on the UK Medical Research Council guidelines for evaluating complex interventions [@bib0055]. The quality of studies was assessed according to the level of evidence for therapy [@bib0060].

3. Evidence synthesis {#sec0015}
=====================

3.1. Assessment of study quality {#sec0020}
--------------------------------

Overall, 43 studies were included; the selection process is displayed in [Figure 1](#fig0005){ref-type="fig"}. The quality of the evidence is low to medium, with no study yielding a level of evidence \>2b ([Table 1 and 2](#tbl0005 tbl0010){ref-type="table"}). Indeed, this classification system attributes the quality mainly according to the study design; therefore, only RCTs or systematic reviews of RCTs, which have not been performed in focal therapy, are classified at higher levels of evidence. Although this suggests that the results of this review should be interpreted with caution, it should be highlighted that several surgical techniques established in clinical practice were based on similar levels of evidence [@bib0065; @bib0070].

Twenty-five series in total were identified that evaluated focal therapy in the primary setting ([Table 1](#tbl0005){ref-type="table"}) [@bib0075; @bib0080; @bib0085; @bib0090; @bib0095; @bib0100; @bib0105; @bib0110; @bib0115; @bib0120; @bib0125; @bib0130; @bib0135; @bib0140; @bib0145; @bib0150; @bib0155; @bib0160; @bib0165; @bib0170; @bib0175; @bib0180; @bib0185; @bib0190; @bib0195]. This equates to 2232 men treated using focal therapy and reported in the literature. Six series used cryosurgery, 12 used high-intensity focused ultrasound (HIFU), 1 used photodynamic therapy (PDT), 3 used photothermal therapy, 1 used radiofrequency interstitial tumour ablation (RITA), 1 used magnetic resonance imaging (MRI)-guided brachytherapy, and 1 incorporated various ablation techniques. Median follow-up periods for the reported focal therapy series are 0--10.6 yr (overall range: 0--11.1 yr).

[Table 2](#tbl0010){ref-type="table"} summarises the eligibility criteria for patients to be included in the five studies evaluating focal salvage therapy in patients with biochemical failure after radical whole-gland radiotherapy [@bib0200; @bib0205; @bib0210; @bib0215; @bib0220]. Apart from one feasibility study investigating the role of RITA in a mixed population of primary and salvage cases, cryoablation, HIFU, and MRI-guided brachytherapy have all been evaluated in a focal manner in patients after external-beam radiation therapy (EBRT) and/or brachytherapy or after proton-beam radiotherapy failure. The number of patients treated in this manner across the series was 115, with a median follow-up of 17--47 mo (range: 3--90 mo).

Thirteen registered trials are evaluating patients treated by focal ablation, with an expected accrual of 989 men [@bib0225; @bib0230; @bib0235; @bib0240; @bib0245; @bib0250; @bib0255; @bib0260; @bib0265; @bib0270; @bib0275; @bib0280; @bib0285]. These trials are using cryosurgery (three trials), HIFU (three trials), PDT (three trials), irreversible electroporation (one trial), MRI-guided thermal therapy (one trial), brachytherapy (one trial), and high dose-rate (HDR) brachytherapy for external beam radiotherapy failure (one trial) ([Table 3](#tbl0015){ref-type="table"}).

3.2. Defining the ideal candidate for focal therapy {#sec0025}
---------------------------------------------------

No overall consensus exists for defining the ideal candidate for primary focal therapy, despite several consensus statements. This reflects different schools of thought with respect to the role of focal therapy in PCa. In 2007, the International Task Force on PCa proposed very conservative criteria for selecting patients, essentially deeming focal therapy an alternative to active surveillance in very low-risk disease [@bib0290]. These criteria were a PSA level \<10 ng/ml, the absence of Gleason grade 4 and 5, the use of extended biopsy schemes, and very restricted biopsy criteria, including maximum length of cancer in each core of 7 mm and maximum percentage of total cores with cancer of 33%. Other consensus groups have attempted to introduce greater flexibility in these criteria by essentially allowing intermediate-risk and some higher-risk PCas, effectively deeming focal therapy an alternative strategy for those men who would normally be advised to have radical therapy [@bib0035; @bib0295; @bib0300; @bib0305].

The criteria used to select candidates for focal therapy in the primary setting do not reflect the conservative approach initially laid down in 2007, and they show a predilection towards intermediate-risk cancer as well as low-risk disease ([Table 1](#tbl0005){ref-type="table"}). Most studies have excluded patients with very low-risk disease and recruited men with presumed unilateral disease. In summary, 1109 men with low-risk disease (56%), 704 men with intermediate-risk disease (36%), and 164 men with high-risk disease (8%) were treated with focal therapy [@bib0075; @bib0080; @bib0085; @bib0090; @bib0095; @bib0100; @bib0105; @bib0110; @bib0115; @bib0120; @bib0125; @bib0130; @bib0135; @bib0140; @bib0145; @bib0150; @bib0155; @bib0160; @bib0165; @bib0170; @bib0175; @bib0180; @bib0185; @bib0190; @bib0195]. Risk categories were not available in 13 series. The PSA level was 3.76--24 ng/ml (overall range: 0.01--82.2 ng/ml), and median age ranged from 56.5 to 73 yr (overall range: 47--80 yr) among the studies. Individual Gleason attribution was available in 20 series, with 1503 men with Gleason score ≤6, 521 with Gleason score 7, and 82 men with Gleason score ≥8.

In focal salvage series, patients were older, with the median age ranging from 65 to 77 yr. Eighty-eight treated men (76%) had failure following EBRT, 17 (15%) after brachytherapy, 2 (2%) after brachytherapy combined with EBRT, and 8 (7%) after proton beam therapy ([Table 2](#tbl0010){ref-type="table"}). No restriction in PSA value or initial risk classification was applied in most studies. However, two series included only patients with presumed unilateral disease [@bib0210; @bib0220].

Of the ongoing trials in the primary setting, four are recruiting only low-risk disease, seven are recruiting low- through intermediate-risk disease, and one has no risk restriction ([Table 3](#tbl0015){ref-type="table"}). Finally, one trial is evaluating focal HDR brachytherapy after EBRT failure.

3.3. Disease localisation {#sec0030}
-------------------------

The spatial location of the tumour within the prostate is essential for focal therapy to deliver treatment. There is no accepted standard for disease localisation for the purpose of delivering focal therapy. The consensus group statements in this area have made recommendations based on limited information at the time of writing. Most have recommended either extended transrectal ultrasound (TRUS) biopsies with strict low-risk criteria or the use of adjunctive imaging, usually multiparametric MRI (mpMRI). Studies have shown that TRUS biopsy is inaccurate for the purposes of identifying candidates for focal therapy and for localising disease [@bib0310; @bib0315; @bib0320; @bib0325; @bib0330; @bib0335; @bib0340; @bib0345; @bib0350]. As a result, most consensus statements have recommended that transperineal template mapping biopsies (TTMBs) are the gold standard for disease localisation for the purpose of focal therapy while accepting that this procedure is more invasive and has health-care resource implications, although the risk of sepsis is negligible [@bib0565; @bib0360; @bib0365; @bib0370; @bib0375; @bib0380; @bib0385; @bib0390; @bib0395]. In addition, there is no consensus as to how many biopsies are sufficient to detect all or most clinically significant cancer. A recent study has shown that TTMB using a 5-mm sampling frame missed only one lesion from a total of 64 lesions that had a volume of ≥0.5 ml and/or had elements of Gleason pattern 4 on subsequent whole-mount radical prostatectomy specimens [@bib0360].

Imaging in the form of a high-quality mpMRI reported by expert radiologists may have the performance characteristics required to localise significant areas of PCa. Evidence is building to show that an area deemed negative on mpMRI stands a 95% probability of having no clinically significant disease as defined by the presence of any Gleason pattern 4 and/or a lesion volume of ≥0.5 ml [@bib0400; @bib0405]. Other ultrasound modalities are demonstrating promise but presently lack the weight of evidence for mpMRI [@bib0410; @bib0570; @bib0420; @bib0425].

In our systematic review, most of the studies used some form of preoperative MRI in combination with biopsy parameters as criteria to select patients; some recent series use this modality for treatment planning ([Table 4 and 5](#tbl0020 tbl0025){ref-type="table"}) [@bib0135; @bib0160; @bib0165; @bib0185; @bib0190; @bib0205]. In summary, among the primary selected studies, two series used only TRUS biopsy, two used TRUS biopsy and Doppler ultrasound, six used TRUS biopsy and MRI, and four used TTMB and mpMRI. The preoperative assessment was not reported in 11 studies.

3.4. Identifying which lesions to target {#sec0035}
----------------------------------------

PCa, as it is currently defined, is multifocal in about 80% of cases on whole-mount pathology, especially if a finer sampling frame of 3 mm is used [@bib0430]. This has generally been regarded as a major limitation in the whole rationale for focal therapy in PCa. Several areas of evidence suggest that multifocality is not necessarily a limiting factor for tissue preservation. First, multifocal disease is present in many other cancers in which tissue-preserving therapy is now standard care [@bib0435; @bib0440; @bib0445; @bib0450]. Second, for PCa, unilateral disease is present in up to one-third of men who have surgery [@bib0350; @bib0455; @bib0460; @bib0465; @bib0470; @bib0475; @bib0480; @bib0485]. Third, there has been increasing debate and gradual acceptance that not all tumours in the prostate behave similarly. The index-lesion concept proposes that it is only the dominant lesion that drives the natural history of the disease [@bib0490; @bib0495; @bib0500; @bib0505]. Indeed, this concept has been extended further by stating that some lesions are clinically significant (likely to have an impact on quality and longevity of life), whereas others are clinically insignificant [@bib0050; @bib0510; @bib0515; @bib0520; @bib0525; @bib0530; @bib0535; @bib0540; @bib0545]. Men who have only clinically insignificant disease have little to no chance of disease progression within their lifetime, and some have proposed they would have no certain benefit in being treated with active therapies [@bib0550].

Current trials have differed in the approach to ablative strategies. Most investigators aim to treat all known areas of cancer in a hemiablative fashion once a man\'s PCa is deemed unilateral. Some trials have deliberately allowed for ablation of the index lesion alone even when multifocal disease is found [@bib0245; @bib0250; @bib0280]. In reality, it is likely that the difference among these trials is very small, since the studies leaving behind untreated cancer for surveillance use biopsy strategies, such as TTMB with 5-mm sampling, that have a high sampling density. Consequently, in these studies, small lesions, which are likely to be missed by other less accurate sampling strategies, are located but are deliberately left untreated.

In summary, all reported series have treated all known areas of cancer, and no reported series have explicitly stated that therapy was aimed at the index lesion and that lesions were deliberately left untreated. Most ongoing trials aim to treat all known areas of cancer, although three trials are explicitly aiming treatment at the index or at clinically significant lesions with surveillance of untreated insignificant lesions ([Table 3](#tbl0015){ref-type="table"}).

In the largest series of 1160 men using cryoablation and in another series using HIFU with multiple strategies (*n* = 88), it was not possible to determine the extent of tissue ablation per patient [@bib0155; @bib0180]. Either hemiablation or focal ablation was used in the remaining studies: 12 used a hemiablation or an extended "dog leg" or hockey stick approach (*n* = 537; relative percentage: 49%), 16 used focal/zonal ablation (*n* = 562; relative percentage: 51%), and 3 used bilateral focal ablation when multifocal disease was present (*n* = 65; relative percentage: 6%) ([Fig. 2](#fig0010){ref-type="fig"}).

3.5. Defining success and failure after focal therapy {#sec0040}
-----------------------------------------------------

Another major challenge in focal therapy is the definition of what constitutes success and failure. The use of disease-specific and overall mortality would require large-scale RCTs, which would likely take 5 yr to recruit and then 10--15 yr of follow-up to obtain sufficient event rates to prove noninferiority over radical whole-gland therapies or superiority over active surveillance. As a surrogate, although PSA outcomes are accepted as a valid outcome in standard therapies, the clinical utility of PSA kinetics in tissue preservation is yet to be determined. Since no PSA outcome measure has been validated in focal therapy yet, the criteria used for defining radiotherapy failure have been used across most of the studies. Thus, the majority of the investigators have reported biochemical outcomes using Phoenix or American Society for Therapeutic Radiology and Oncology (ASTRO) criteria [@bib0555]. However, these criteria are neither validated nor appropriate for ablative techniques, not only because there is prostatic tissue remaining but also because the mechanism of cell death is different between radiation therapy and immediate ablation, so PSA kinetics are likely to be different. Some have proposed using the Stuttgart definition developed for whole-gland HIFU [@bib0560]. One study investigated the biochemical disease-free survival (bDFS) predictive value, verified by follow-up biopsy, of Phoenix criteria alone or Phoenix associated with PSA velocity \<0.75 ng/ml per year [@bib0185]. The authors found that the compound strategy could predict biopsy-proven failure better than Phoenix criteria alone. If PSA kinetics are used to define focal therapy outcomes, it is likely that such models will have to incorporate the fact that untreated tissue is still PSA secreting and a threshold PSA for failure may have to incorporate an estimation of the extent of prostatic tissue ablated. However, until a validated PSA measure is found, an international consensus is needed about what might constitute biochemical failure after focal therapy, so that medium-term outcomes can be used to allow comparison between individual focal-therapy series, and between focal therapy and standard care.

Our systematic review of focal-therapy series demonstrates the summary outcomes presented in the following section and in [Table 4--7](#tbl0020 tbl0025 tbl0030 tbl0035){ref-type="table"}. Furthermore, [Table 3](#tbl0015){ref-type="table"} shows outcomes used in prospective registered clinical trials that have not yet been reported.

3.6. Current outcomes in respect of focal therapy in the primary setting {#sec0045}
------------------------------------------------------------------------

### 3.6.1. Side effects, complications, and quality of life {#sec0050}

[Table 6](#tbl0030){ref-type="table"} summarises the morbidity and functional outcome of the studies selected. Median length of hospital stay was 1 d; other perioperative outcomes were poorly reported, with only one study using a standardised classification of these outcomes (Dindo-Clavien classification) [@bib0195]. The incidences of the most frequent complications, namely, urinary retention, urinary stricture, and urinary tract infection, ranged from 0% to 17%, from 0% to 5%, and from 0% to 17%, respectively. Only five studies actually reported all of these [@bib0125; @bib0145; @bib0150; @bib0175; @bib0195].

Urinary functional outcomes were reported using validated questionnaires in nine studies; physician-reported rates were used in five studies. Using validated questionnaires, the pad-free continence rate varied between 95% and 100%, and the range of leak-free rates was 83--100%.

Erectile function was reported using validated questionnaires in 10 studies and using physician-reported rates in three studies. Considering only trials evaluating focal therapy with *intention to treat*, when validated questionnaires were used, erectile function sufficient for penetration was reported in 54--100% of patients (with or without PDE5-I medication). Physician-reported rates ranged from 58.1% to 85%.

Rectal toxicity was often poorly reported. When it was reported, rates of fistula ranged from 0% to 1%; one series reported one of 41 men suffering grade 3 rectal toxicity conservatively managed as a possible rectourethral fistula [@bib0175]. Finally, patient-reported outcomes evaluating overall QOL were uncommonly used in these studies, with only three publications reporting them.

### 3.6.2. Cancer control {#sec0055}

Apart from early feasibility trials (*n* = 6) that verified the effect of tissue ablation by analysis of radical whole-mount prostatectomy specimens, nine series incorporated routine, mandatory, postfocal therapy biopsies in their protocol. In the six early series, residual disease was found in 73 of 74 men who had undergone radical prostatectomy. Although this rate seems excessively high, it should be noted that being early stage 0/1 trials, the main objective was to assess the safety of the sources of energies without actually attempting to ablate all the disease present.

Of the remaining nine series, biopsies were performed only on the treated side in three series; in the other six, biopsy specimens also were taken on the contralateral side. When post-therapy biopsy procedures were routinely offered, clinically significant cancer was present in 0--17% (*n* = 202). When clinically insignificant cancer also was taken into account (excluding one feasibility trial that evaluated safety rather than ablation), 4--50% of men had positive biopsy results after treatment (*n* = 255). When biopsy procedures were offered only *for cause*, overall positive biopsy rates of 13--71% were demonstrated for all types of cancer; when considering all patients enrolled in these series, this percentage range was 3.7--23%. None of these series reported the percentage of significant cancer among patients undergoing a biopsy.

Two series evaluated the presence of residual tumour in the treated area; this amounted to 3--14% when considering only patients undergoing a biopsy and from 1.7% to 3.9% when the denominator was all treated patients.

Biochemical control was reported using Phoenix criteria in five series. Other definitions used were ASTRO (five series), Stuttgart (one series), and Phoenix plus PSA velocity \>0.75 ng/ml per year (one series). The results range from 86.2% at 8-yr follow-up (*n* = 318 men) to 60% at 5 yr (*n* = 56) [@bib0120; @bib0185].

Only 12 series reported the need for secondary focal treatments, with a range of 0--34%. Salvage local treatments were reported in 14 series with rates of 0--33%. One feasibility trial had higher secondary focal (67%) and salvage treatment (83%); these upper percentages were not considered in the overall range, since the intent to treat was not to destroy all tumour [@bib0095].

The progression to metastatic disease is not reported in most of the studies, as the follow-up is too short to have a significant percentage of patients develop metastasis. Nevertheless, when it is indicated, it is extremely low (0--0.3%).

Cancer-specific survival was extremely high in these studies, as expected with the small numbers and short follow-up inherent in almost all reported series; only three studies had a follow-up \>5 yr. No man died of PCa after focal therapy in the defined follow-up period. Four men died of other causes in the follow-up period. The very low mortality rate was as expected with the short follow-up and the inclusion of many men with low-risk disease, which has a prolonged natural history.

3.7. Current outcomes of focal salvage therapy for failure after radiation therapy {#sec0060}
----------------------------------------------------------------------------------

### 3.7.1. Side effects, complications, and quality of life {#sec0065}

The toxicity and QOL outcomes for focal therapy after radiation failure are reported in [Table 7](#tbl0035){ref-type="table"} from five published series with a total of 115 men treated. The small numbers considerably limit the generalizability of these findings. Continence, estimated by pad-free rate, was achieved in 87.2--100% of patients. Erectile function was poorly reported, possibly as a result of poor baseline function. However, in three studies (*n* = 82), potency was preserved in 29--40% of previously potent patients [@bib0210; @bib0215; @bib0220]. The rate of rectourethral fistula (0--12%) was significantly higher than in the primary cases.

### 3.7.2. Oncologic outcome {#sec0070}

Follow-up was a median range of 17--47 mo. Apart from one feasibility trial, in which the positive biopsy rate for all cancer was 50% in all areas and 33% in the treated area, residual cancer was found in 8--10% of patients using TRUS biopsy [@bib0200; @bib0210; @bib0220]. However, this percentage was as high as 44% using TTMB, if considering only patients who had a *for cause* biopsy as the denominator. When considering all patients treated, the positive biopsy rate was 10% [@bib0215]. Only one series reported the presence of residual significant cancer, and it showed a rate of 8% [@bib0220].

Biochemical disease-free rates in the longest series using the Phoenix criteria were 70% and 54% at 4 and 5 yr, respectively [@bib0205; @bib0220]. In one series, the bDFS at 2 yr was significantly lower at 42% using the Stuttgart criteria [@bib0215]. Salvage treatment was given to 8--41% of patients, and metastatic disease was diagnosed in 5--20%. Overall survival was 100% in the two series that reported this outcome [@bib0200; @bib0220].

4. Discussion {#sec0075}
=============

This systematic review highlights that when focal therapy is delivered with intention to treat, the perioperative, functional, and disease control outcomes are encouraging.

Although our systematic review was, by its nature, thorough, there were areas that we could not evaluate but that are pertinent to the debate surrounding focal therapy. First, in the light of new findings regarding PCa pathology and natural history, it appears clear that focal therapy should targeted to patients who are likely to benefit from active treatment, whereas men with clinically insignificant disease should be monitored carefully by active surveillance. Specifically, patients with clinically significant disease localised only in one area of the prostate should be considered the optimal candidates for a focal approach.

Second, accurate localisation of disease is essential with mpMRI or novel ultrasound modalities with targeted biopsy of suspicious areas, when available; equally, TTMB may also form part of a rigorous preoperative assessment.

Third, patients treated with an organ-preserving approach must be monitored with strategies similar to active surveillance protocols. Indeed, the presence of significant undetected disease, residual disease, cancer progression, or de novo cancer are all possibilities that mandate active monitoring. However, although the follow-up of men after organ-sparing approaches requires measuring the PSA level, this will not sufficient by itself until validated biochemical measures are developed. Biopsy of the treated and untreated areas are required in the interim, although MRI may play a role in the future if it can be validated for detecting local failure against histologic outcomes.

Fourth, before focal therapy becomes an alternative standard option across the board, it should be highlighted that many issues remain to be addressed, including determining which ablative technology has better functional and oncologic outcome, the margin of normal tissue required, and the long-term disease-control outcomes. In addition, the encouraging results of focal therapy that we report here are the outcomes of a few experienced centres; their generalizability has yet to be proven and training and quality control will be key factors driving the dissemination further.

Finally, we did not address the level of evidence that should drive change. In the studies included, no prospective development study was powered on oncologic outcome, and only two series had a follow-up \>5 yr; therefore, no significant conclusion on disease control could be derived. Certainly, high-quality effectiveness studies comparing focal therapy to standard treatments (level 1 evidence) are needed to change practice.

The design of future effectiveness trials comparing focal to whole-gland therapies is debatable. Some have argued for long-term mortality outcomes; however, if this were the case, progress and change would be prohibitively delayed because the studies required for mortality outcomes are likely to take 15--20 yr to deliver data and unlikely to recruit. If mortality is out of reach and biochemical outcomes are implausible, at least for the time being, then other more pragmatic outcomes will be necessary. These are likely to include (1) treatment-specific and overall QOL measures, (2) local cancer control measured as absence of significant PCa, (3) rate of additional systemic therapy, and (4) cost effectiveness.

The first pragmatic outcome relates to treatment-related side effects and can be relatively well captured in the short term using validated questionnaires. These are principally directed at genitourinary and bowel-associated outcomes and have been used in the evaluation of all the interventions under consideration. The second pragmatic outcome relates to effectiveness of local cancer control. Histologic confirmation of complete ablation within the treated area appears to be essential when a man is treated with focal therapy, given the uncertainty of PSA follow-up. However, TRUS biopsy would have the same inherent random and systematic sampling errors when used after treatment and may not be reliable in determining the absence of residual disease. At present, TTMB appears to be one of a number of accurate tools for confirming the effectiveness of the treatment, as the possibility of missing significant PCa is \<5% with this technique [@bib0360]. In contrast, some investigators have used mpMRI to assess recurrence and the initial results seem promising. In two studies of patients treated with focal HIFU, one including 20 patients and the other 41, no significant cancer was found in the treated area when mpMRI did not show signs of residual disease [@bib0150; @bib0175].

The third pragmatic outcome, use of additional systemic therapy, could be regarded as the only acceptable outcome measure that would cover focal therapy and standard care objectively. This outcome should clearly be separated from the need for additional local treatment or local failure. Indeed, secondary ablation with the same or a different energy applied in a focal manner probably should not be incorporated in this pragmatic outcome as a failure although the application of whole-gland therapy using any modality would constitute failure at that point in time. In other words, this pragmatic outcome should count as failure when there is a change in strategy from focal to whole-gland ablation or the direct shift to systemic therapy; this would allow realistic comparison with standard treatments. This would have to be verified by evidence that men who have second or even third focal treatments do not suffer worse genitourinary and disease-control rates compared to men who have radical treatments. Finally, the effectiveness of each therapy should be balanced with its cost to allow objective comparisons between different active treatments.

5. Conclusions {#sec0080}
==============

Although focal therapy may be regarded as an alternative to active surveillance by many physicians, it should not be proposed to patients with confirmed, clinically insignificant, low-risk disease who are unlikely to benefit from any form of treatment and in whom even focal therapy would be regarded as an overtreatment. Robust effectiveness studies are now required to compare focal therapy to radical therapy in men with clinically significant PCa.
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###### 

Target population with stage of evaluation and level of evidence of 25 studies using focal therapy in the primary setting

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                                                                                                                                                Eligibility criteria                                                                                 
  ------------------------------------------------------------------ --------- ---- ---------------------------------------------------------- ------ ------------------------------ -------------------------------------------------------------------- ------------------------- ------------------------------------------- ----------------------------------------------- ---------------- ---------------- ------------------ ----
  Madersbacher et al. [@bib0075]                                     Primary   1    NR                                                         29     Mean: 64 (SD: 7.2)             NR                                                                   NR                        NR                                          Unilateral                                      NR               NR               NR                 2c

  Zlotta et al. [@bib0080]                                           Primary   1    NR                                                         15     NR                             NR                                                                   NR                        NR                                          Organ confined                                  NR               NR               NR                 2c

  Beerlage et al. [@bib0085]                                         Primary   1    NR                                                         14     Mean: 62 (range: 55--69)       TRUS biopsy                                                          MRI\                      NR                                          NR                                              NR               NR               NR\                2c
                                                                                                                                                                                                                                                          Bone scan                                                                                                                                                                  

  Souchon et al. [@bib0090]                                          Primary   1    NR                                                         2      NR                             NR                                                                   MRI                       NR                                          Organ confined                                  NR               NR               NR                 2c

  Moore et al. [@bib0095]                                            Primary   1    No                                                         6      Median: 66 (range: 61--71)     TRUS biopsy                                                          MRI\                      NR                                          Organ confined                                  ≤15              ≤3 + 3           NR                 2c
                                                                                                                                                                                                                                                          Bone scan                                                                                                                                                                  

  Bahn et al. [@bib0100]                                             Primary   2a   NR                                                         31     Mean: 63 (range or SD: NR)     TRUS sextant biopsy plus target biopsy of suspicious areas           TRUS Doppler evaluation   ASTRO                                       Unilateral                                      NR               NR               NR                 4

  Onik et al. [@bib0105]                                             Primary   2a   25 (45%) received short-term ADT (stopped at treatment)    55     NR                             TRUS 10-core biopsy or transperineal template biopsy                 NR                        ASTRO                                       NR                                              NR               NR               NR                 4

  Ellis et al. [@bib0110]                                            Primary   2a   NR                                                         60     Mean: 69 (SD: 7.8)             NR                                                                   NR                        ASTRO                                       NR                                              NR               NR               NR                 4

  Muto et al. [@bib0115]                                             Primary   2a   7 (24.1%) received short-term ADT (stopped at treatment)   29     Median: 72 (range: 62--80)     TRUS \>12-core biopsy                                                MRI                       ASTRO                                       Unilateral                                      NR               NR               NR                 3b

  Murat et al. [@bib0120]                                            Primary   2a   NR                                                         56     Mean: 65.6 (range or SD: NR)   NR                                                                   NR                        Phoenix                                     Unilateral                                      NR               NR               Low-intermediate   4

  Lindner et al. [@bib0125]                                          Primary   1    No                                                         12     Median: 56.5 (range: 51--62)   TRUS 12-core biopsy                                                  MRI                       NR                                          Tumour located in 1 of 12 core biopsy sectors   \<10             ≤3 + 3           Low                2c

  Lindner et al. [@bib0130]                                          Primary   1    NR                                                         4      Median: 66 (range: 61--73)     NR                                                                   NR                        NR                                          NR                                              NR               NR               NR                 4

  Raz et al. [@bib0135]                                              Primary   1    NR                                                         2      73                             NR                                                                   MRI                       NR                                          NR                                              NR               NR               NR                 4

  Truesdale et al. [@bib0140]                                        Primary   2b   No                                                         77     Mean: 69.5 (SD: 6.7)           TRUS biopsy                                                          CT\                       Phoenix                                     Unilateral                                      NR               NR               NR                 4
                                                                                                                                                                                                                                                          Bone scan                                                                                                                                                                  

  El Fegoun et al. [@bib0145]                                        Primary   2a   No                                                         12     Mean: 70 (SD: 4.8)             NR                                                                   CT\                       Phoenix                                     Unilateral                                      ≤10              ≤3 + 4           Low-intermediate   4
                                                                                                                                                                                                                                                          Bone scan                                                                                                                                                                  

  Ahmed et al. [@bib0150]                                            Primary   2a   No                                                         20     Mean: 60.4\                    Transperineal template biopsy                                        MRI                       NR                                          Unilateral                                      ≤15              ≤4 + 3           Low-intermediate   2b
                                                                                                                                                      (SD: 5.4)                                                                                                                                                                                                                                                                      

  Ward et al. [@bib0155]                                             Primary   2b   NR                                                         1160   Mean: 67.8 (SD: 7.8)           NR                                                                   NR                        ASTRO                                       No restriction                                  No restriction   No restriction   No restriction     4

  Tay et al. [@bib0160]                                              Primary   1    No                                                         9      NR                             NR                                                                   MRI                       NR                                          NR                                              \<10             ≤3 + 3           Low                4

  Chopra et al. [@bib0165]                                           Primary   1    No                                                         8      Mean: 60 (range: 49--70)       TRUS 12-core biopsy                                                  MRI                       NR                                          NR                                              ≤15              ≤4 + 3           Low-intermediate   2c

  Bahn et al. [@bib0170][\*](#tblfn0005){ref-type="table-fn"}        Primary   2b   13 (18%) received short-term ADT (stopped at treatment)    73     Median: 64\                    TRUS sextant biopsy plus mapping target biopsy of suspicious areas   TRUS Doppler evaluation   NR                                          Unilateral                                      ≤20              ≤4 + 3           Low-intermediate   4
                                                                                                                                                      (range: 47--79)                                                                                                                                                                                                                                                                

  Ahmed et al. [@bib0175]                                            Primary   2a   No                                                         41     Median: 63 (range: 58--66)     Transperineal template biopsy                                        MRI                       NR                                          Unilateral and bilateral                        ≤15              ≤4 + 3           Low-intermediate   2b

  Dickinson et al. [@bib0180][\*](#tblfn0005){ref-type="table-fn"}   Primary   2a   No                                                         88     Median: 64 (range: 48--75)     Transperineal template biopsy                                        MRI                       Phoenix and Stuttgart                       Unilateral and bilateral                        \<20             ≤4 + 3           Low-intermediate   2b

  Nguyen et al. [@bib0185]                                           Primary   2b   No                                                         318    NR                             TRUS biopsy (sextant between 1997--2003, then 10--12 cores)          MRI                       Phoenix (and Phoenix plus PSAV \>0.75/yr)   No tumour beyond peripheral zone                \< 15            ≤3 + 4           Low-intermediate   4

  Napoli et al. [@bib0190]                                           Primary   1    No                                                         5      Median: 65.4 (range: 50--75)   NR                                                                   MRI                       NR                                          Unilateral and unifocal                         NR               ≤4+ 3            Low-intermediate   2c

  Barret et al. [@bib0195]                                           Primary   2b   No                                                         106    Mean: 66.5 (IQR: 61--73)       Transperineal template biopsy (97%) and TRUS 12-core biopsy (100%)   MRI                       NR                                          Unilateral                                      \<10             ≤3 + 3           Low                4
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

bDFS = biochemical disease-free survival; PSA = prostate-specific antigen; NCCN = National Comprehensive Cancer Network; NR = not reported; SD = standard deviation; TRUS = transrectal ultrasound; MRI = magnetic resonance imaging; ASTRO = American Society for Therapeutic Radiology and Oncology; CT = computed tomography; ADT = androgen-deprivation therapy; PSAV = prostate-specific antigen velocity; IQR = interquartile range.

This series partially overlaps with one previously reported.

###### 

Target population with stage of evaluation and level of evidence of the five studies using focal therapy in the primary setting

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                                                                                                                   Eligibility criteria                                            
  ----------------------------- -------------------- ---- ------------------------------------------------------------------------------------------ ---- ---------------------------- -------------------------------------------------------------------- -------------- ----------------------- ---------------------- ------ ---------------- ---------------- ----
  Shariat et al. [@bib0200]     Salvage (*n* = 8)\   1    EBRT: 8 (73)                                                                               11   Median: 77 (range: 60--82)   TRUS 12-core biopsy                                                  NR             NR                      NR                     NR     NR               NR               2c
                                Primary (*n* = 3)                                                                                                                                                                                                                                                                                                                  

  Nguyen et al. [@bib0205]      Salvage              2a   EBRT: 12 (48)\                                                                             25   Median: 65 (range: 56--82)   TRUS biopsy                                                          CT or MRI\     Phoenix                 NR                     \<10   ≤4 + 3           NR               2b
                                                          Brachytherapy: 12 (48)\                                                                                                                                                                           Bone scan                                                                                              
                                                          Brachytherapy plus EBRT: 1 (4)                                                                                                                                                                                                                                                                           

  Eisenberg et al. [@bib0210]   Salvage              2a   EBRT with some men (*n* = NR) receiving permanent seed implantation and/or ADT: 18 (100)   18   Mean: 70.6 (range: 58--86)   TRUS 16-core biopsy                                                  CT\            ASTRO and Phoenix       Unilateral             NR     NR               NR               4
                                                                                                                                                                                                                                                            Bone scan                                                                                              

  Ahmed et al. [@bib0215]       Salvage              2b   EBRT: 39 (100)\                                                                            39   Mean: 70.5 (SD: 6.8)         Transperineal template biopsy (*n* = 20) or TRUS biopsy (*n* = 19)   MRI\           Phoenix and Stuttgart   NR                     NR     NR               NR               4
                                                          Short-term ADT (stopped at treatment): 13 (33)                                                                                                                                                    FDG-PET                                                                                                

  Abreu et al. [@bib0220]       Salvage              2b   EBRT: 11 (44)\                                                                             25   Median: 71 (range: 59--81)   TRUS sextant biopsy plus mapping target biopsy of suspicious areas   TRUS Doppler   Phoenix                 Unilateral             ≤20    No restriction   No restriction   3b
                                                          Proton beam radiotherapy: 8 (32)\                                                                                                                                                                                                                                                                        
                                                          Brachytheraphy: 5 (20)\                                                                                                                                                                                                                                                                                  
                                                          Brachytheraphy plus EBRT: 1 (4)\                                                                                                                                                                                                                                                                         
                                                          Short-term ADT (stopped at treatment): 9 (36)                                                                                                                                                                                                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

bDFS = biochemical disease-free survival; PSA = prostate-specific antigen; NCCN = National Comprehensive Cancer Network; EBRT = external beam radiation therapy; TRUS = transrectal ultrasound; NR = not reported; CT = computed tomography; MRI = magnetic resonance imaging; ADT = androgen-deprivation therapy; ASTRO = American Society for Therapeutic Radiology and Oncology; FDG-PET = 2-deoxy-2-\[F-18\]fluoro-D-glucose positron emission tomography.

###### 

The design of the ongoing 13 registered trials investigating focal therapy using various sources of energy

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                                                                                           Eligibility criteria                                                                                                                                                                                                                                  
  --------------------- --------------------------------------------------------- --------------------------------------------- ----- --------- ------------------------------------------ ------------------------------------------------------------------------- ------------------- --------------- ------------------ ---- ------------------------- -------------------------------------------------------------------------------- ---- --------------------
  Eggener [@bib0225]    University of Chicago                                     [NCT01192438](ctgov:NCT01192438){#intr0005}   9     Primary   MRI-guided laser-induced thermal therapy   NR                                                                        NR                  ≤4 + 3          Low-intermediate   6    Safety                    NR                                                                               2a   Completed (NR)

  Taneja [@bib0230]     NYU Urology Associates (multicentre)                      [NCT00946881](ctgov:NCT00946881){#intr0010}   30    Primary   PDT                                        Unilateral tumour                                                         \<10                3 + 3           Low                12   Safety                    \- Cancer control (biopsy)\                                                      2a   Completed (NR)
                                                                                                                                                                                                                                                                                                                                                           - QOL outcome                                                                         

  Emberton [@bib0235]   University College London Hospitals (multicentre)         [NCT00975429](ctgov:NCT00975429){#intr0015}   86    Primary   PDT                                        NR                                                                        \<10                ≤3 + 4          Low-intermediate   6    Cancer control (biopsy)   \- Urinary outcome (IPSS)\                                                       2b   Completed (NR)
                                                                                                                                                                                                                                                                                                                                                           - Erectile outcome (IIEF)\                                                            
                                                                                                                                                                                                                                                                                                                                                           - QOL outcome                                                                         

  Emberton [@bib0240]   University College London Hospitals (multicentre)         [NCT01310894](ctgov:NCT01310894){#intr0020}   200   Primary   PDT                                        Unilateral tumour                                                         ≤10                 3 + 3           Low                24   Cancer control (biopsy)   \- Urinary outcome\                                                              2b   Recruiting
                                                                                                                                                                                                                                                                                                                                                           - Erectile outcome\                                                                   
                                                                                                                                                                                                                                                                                                                                                           - QOL outcome                                                                         

  Emberton [@bib0245]   University College London Hospitals (multicentre)         [NCT01194648](ctgov:NCT01194648){#intr0025}   272   Primary   HIFU                                       Unilateral clinically significant disease                                 ≤15                 ≤4 + 3          Low-intermediate   36   Cancer control (biopsy)   \- Urinary outcome (IPSS and UCLA-EPIC urinary domain)\                          2b   Recruiting
                                                                                                                                                                                                                                                                                                                                                           - Erectile outcome (IIEF-15)\                                                         
                                                                                                                                                                                                                                                                                                                                                           - Rectal outcome (UCLA-EPIC bowel domain)\                                            
                                                                                                                                                                                                                                                                                                                                                           - QOL (EQ-5D and RAND 36-item Health Survey125)                                       

  Ahmed [@bib0250]      University College London Hospitals                       [NCT00987675](ctgov:NCT00987675){#intr0030}   56    Primary   HIFU                                       Any localisation, but preservation of at least one neurovascular bundle   \<20                ≤8              All risks          12   Safety                    \- Cancer control (biopsy and PSA kinetics)\                                     2a   Recruiting
                                                                                                                                                                                                                                                                                                                                                           - Urinary outcome (IPSS and UCLA-EPIC urinary domain)\                                
                                                                                                                                                                                                                                                                                                                                                           - Erectile outcome (IIEF-15)\                                                         
                                                                                                                                                                                                                                                                                                                                                           - Rectal outcome (UCLA-EPIC bowel domain)\                                            
                                                                                                                                                                                                                                                                                                                                                           - QOL (FACT-P)                                                                        

  Guazzoni [@bib0255]   Università Vita-Salute San Raffaele                       [NCT00928603](ctgov:NCT00928603){#intr0035}   100   Primary   Cryoablation                               Tumours in the transition zone are excluded                               \<10                3 + 3           Low                60   Safety                    \- Cancer control\                                                               2b   Recruiting
                                                                                                                                                                                                                                                                                                                                                           - Urinary outcome (IPSS)\                                                             
                                                                                                                                                                                                                                                                                                                                                           - Erectile outcome (IIEF-15)\                                                         
                                                                                                                                                                                                                                                                                                                                                           - QOL (FACT-P and MSKCC Prostate-Health Related Quality of Life Questionnaire)        

  Napoli [@bib0260]     University of Roma La Sapienza                            [NCT01522118](ctgov:NCT01522118){#intr0040}   12    Primary   MRI-guided HIFU                            NR                                                                        ≤10                 ≤3 + 4          Low-intermediate   18   Safety                    \- Cancer control (biopsy)                                                       2a   Recruiting

  Zelefsky [@bib0265]   Memorial Sloan-Kettering Cancer Centre                    [NCT01354951](ctgov:NCT01354951){#intr0045}   80    Primary   Brachytherapy                              Unilateral tumour                                                         \<10                ≤3 + 4          Low-intermediate   24   Safety\                   \- Cancer control (biopsy)\                                                      2b   Recruiting
                                                                                                                                                                                                                                                                                                                                 (NCI CTCAE)               - QOL (MSKCC Prostate-Health Related Quality of Life Questionnaire)                   

  Ward [@bib0270]       UT MD Anderson Cancer Centre                              [NCT00877682](ctgov:NCT00877682){#intr0050}   100   Primary   Cryoablation                               NR                                                                        ≤10                 ≤3 + 4          Low-intermediate   36   Cancer control (biopsy)   \- Urinary outcome\                                                              2b   Recruiting
                                                                                                                                                                                                                                                                                                                                                           - Erectile outcome\                                                                   
                                                                                                                                                                                                                                                                                                                                                           - Rectal outcome\                                                                     
                                                                                                                                                                                                                                                                                                                                                           - QOL outcome                                                                         

  Eastham [@bib0275]    Memorial Sloan-Kettering Cancer Centre\                   [NCT00774436](ctgov:NCT00774436){#intr0055}   50    Primary   Cryoablation                               NR                                                                        \<10                NR              Low                6    Cancer control (biopsy)   \- QOL                                                                           2b   Not yet recruiting

  Emberton [@bib0280]   University College London Hospitals                       [NCT01726894](ctgov:NCT01726894){#intr0060}   20    Primary   Irreversible electroporation               Anterior tumour                                                           ≤15                 ≤4 + 3          Low-intermediate   12   Safety\                   \- Cancer control (biopsy)\                                                      2a   Not yet recruiting
                                                                                                                                                                                                                                                                                                                                 (NCI CTCAE)               - Urinary outcome (IPSS and UCLA-EPIC urinary domain)\                                
                                                                                                                                                                                                                                                                                                                                                           - Erectile outcome (IIEF-15)\                                                         
                                                                                                                                                                                                                                                                                                                                                           - Rectal outcome (UCLA-EPIC bowel domain)\                                            
                                                                                                                                                                                                                                                                                                                                                           - QOL (EQ-5D, FACT-P and Memorial Anxiety scale)                                      

  Chung [@bib0285]      Sunnybrook Health Sciences Centre, Odette Cancer Centre   [NCT01583920](ctgov:NCT01583920){#intr0065}   4     Salvage   HDR brachytherapy                          Recurrence confined to the prostate                                       \<10\               ≤ 4 + 3\        Low-intermediate   60   Safety\                   \- Cancer control (bDFS)\                                                        2a   Not yet recruiting
                                                                                                                                                                                                                                                                     ≤20 (before EBRT)   (before EBRT)                           (NCI CTCAE)               - Urinary outcome (IPSS)\                                                             
                                                                                                                                                                                                                                                                                                                                                           - QOL (UCLA-EPIC)                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PSA = prostate-specific antigen; NCCN = National Comprehensive Cancer Network; MRI = magnetic resonance imaging; NR = not reported; PDT = photodynamic therapy; QOL = quality of life; IPSS = International Prostate Symptom Score; IIEF = International Index of Erectile Function; HIFU = high-intensity focused ultrasound; UCLA-EPIC = University of California, Los Angeles-Expanded Prostate Cancer Index Composite; EQ-5D = EuroQol-5 dimensions; RAND 36 = RAND 36-item health survey; FACT-P = Functional Assessment of Cancer Therapy-Prostate; NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events; MSKCC = Memorial Sloan-Kettering Cancer Center; HDR = high dose rate; bDFS = biochemical disease-free survival.

###### 

Actual population studied in each primary series with the histologic, biochemical, and cancer long-term outcomes

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                            Technology                 Type of ablation                                                 PSA level, ng/ml                   Gleason score at preoperative biopsy (%)   Risk classification, D'Amico or NCCN, no. (%)   Follow-up                            Postfocal histology (reason)                                                       Presence of any cancer, actual (%)                                   Presence of clinically significant cancer   bDFS, %                        PSA kinetics[\*](#tblfn0010){ref-type="table-fn"}   Secondary treatment, actual (%)            Metastatic disease, actual (%)   Mortality: %
  -------------------------------------------------------------------- -------------------------- ---------------------------------------------------------------- ---------------------------------- ------------------------------------------ ----------------------------------------------- ------------------------------------ ---------------------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------- ------------------------------ --------------------------------------------------- ------------------------------------------ -------------------------------- --------------------------------------------
  Madersbacher et al. [@bib0075]                                       HIFU                       Midline target or unilateral ablation of TRUS-visible tumours    Mean: 24 (range: 2--82.8)          NR                                         NR                                              Few hours (mean/median: NR)          RP                                                                                 29/29 (100)                                                          NR                                          NR                             NR                                                  NR                                         NR                               Overall and cancer-specific survival: 100

  Zlotta et al. [@bib0080]                                             RITA                       Multifocal                                                       NR                                 NR                                         NR                                              Mean/median: NR (range: 0 d--3 mo)   RP                                                                                 14/14 (100)                                                          NR                                          NR                             NR                                                  NR                                         NR                               Overall and cancer-specific survival: 100

  Beerlage et al. [@bib0085]                                           HIFU                       Total or subtotal hemiablation                                   Mean: 10.8 (range: 3.5--20)        NR                                         NR                                              Median: 8.5 d (range: 7--12)         RP                                                                                 13/14 (93)\                                                          NR                                          NR                             NR                                                  0/14 (0)                                   0/14 (0)                         Overall and cancer-specific survival: 100
                                                                                                                                                                                                                                                                                                                                                                                                                         4/14 (29) had residual tumor in treated area                                                                                                                                                                                                                                    

  Souchon et al. [@bib0090]                                            HIFU                       Focal ablation of peripheral zone                                NR                                 NR                                         NR                                              NR                                   NR                                                                                 NR                                                                   NR                                          NR                             NR                                                  NR                                         NR                               NR

  Moore et al. [@bib0095]                                              PDT                        Focal with ipsilateral peripheral zone ablation                  Median: 6.95 (range: 1.9--15)      3 + 3: 6 (100)                             NR                                              NR                                   TRUS sextant biopsy (protocol)                                                     6/6 (100)                                                            NR                                          NR                             NR                                                  4/6 (67) redo PDT\                         0/6 (0)                          Overall and cancer-specific survival: 100
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             5/6 (83) salvage treatment (3 EBRT,\                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             1 brachytherapy,\                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             1 cryotherapy)                                                              

  Bahn et al. [@bib0100]                                               Cryoablation               Hemiablation                                                     Mean: 4.95 (range or SD: NR)       ≤6: 23 (74)\                               NR                                              Mean: 70 mo (range: 2--107)          TRUS sextant biopsy plus target biopsy of suspicious areas on Doppler (protocol)   1/25 (4)                                                             NR                                          92.9                           NR                                                  1/31 (4) redo cryoablation                 0/25 (0)                         Overall survival: 96\
                                                                                                                                                                                                      7: 8 (26)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Cancer-specific survival: 100

  Onik et al. [@bib0105]                                               Cryoablation               Focal                                                            Mean: 8.3 (range or SD: NR)        NR                                         Low: 26 (48)\                                   Mean: 3.6 yr (range: 1--10)          NR                                                                                 Only patients having biopsy: 4/30 (13)\                              NR                                          95 (3 yr)                      Mean: 2.4 (SD: NR)                                  4/55 (7) redo cryoablation                 NR                               Overall and cancer-specific survival: 100
                                                                                                                                                                                                                                                 Intermediate: 20 (36)\                                                                                                                                                  All patients: 4/55 (7)                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                 High: 9 (16)                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Ellis et al. [@bib0110]                                              Cryoablation               Hemiablation plus contralateral peripheral zone (hockey stick)   Mean: 7.2 (SD: 4.7)                ≤6: NR (78.3)\                             Low: 40 (66.7)\                                 Median: 12 mo (range: 3--36)         NR                                                                                 Only patients having biopsy: 14/35 (40); 1/35 (3) in treated side\   NR                                          80.4                           Median: 1.7 (IQR: NR)                               11/60 (18) redo cryoablation               0/60 (0)                         Overall and cancer-specific survival: 100
                                                                                                                                                                                                      7: NR (20)\                                Intermediate: 14 (23.3)\                                                                                                                                                All patients: 14/60 (23); 1/60 (1.7) in treated side                                                                                                                                                                                                                            
                                                                                                                                                                                                      ≥8 NR (1.7)                                High: 6 (10)                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Muto et al. [@bib0115]                                               HIFU                       Hemiablation plus contralateral peripheral zone (hockey stick)   Median: 5.4 (range: 0.2--25.1)     Unknown: 2 (6.9)\                          NR                                              Median: 34 mo (range: 8--45)         TRUS sextant (protocol)\                                                           At 6 mo: 3/28 (10.7)\                                                NR                                          2-yr\                          36-mo mean: 1.89 (SD: 1.51)                         7/29 (24) ADT                              NR                               Overall and cancer-specific survival: 100
                                                                                                                                                                                                      ≤6: 16 (55.2)\                                                                                                                                                                                                     At 12 mo: 4/17 (23.5)\                                                                                           Low risk: 83.3\                                                                                                                                                
                                                                                                                                                                                                      7: 6 (20.7)\                                                                                                                                                                                                                                                                                                                        Intermediate risk: 53.6                                                                                                                                        
                                                                                                                                                                                                      ≥8: 5 (17.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Murat et al. [@bib0120]                                              HIFU                       Hemiablation                                                     NR                                 NR                                         Low: 33 (59)\                                   Median: 42 mo (NR)                   NR                                                                                 NR                                                                   NR                                          3 yr: 76\                      Nadir after first HIFU: mean: 0.5 (SD: NR)\         19/56 (34) redo HIFU                       NR                               NR
                                                                                                                                                                                                                                                 Intermediate: 23 (41)                                                                                                                                                                                                                                                                    5 yr: 60                       Nadir after redo HIFU: mean: 0.47 (SD: NR)                                                                                      

  Lindner et al. [@bib0125]                                            Photothermal laser         Focal                                                            Mean: 5.7\                         3 + 3: 12 (100)                            Low risk: 12 (100)                              6 mo                                 TRUS 10-core biopsy plus 2 cores guided in the treated area (protocol)             6/12 (50)\                                                           2/12 (17)                                   NR                             NR                                                  1/12 (8) RP                                0/12 (0)                         Overall and cancer-specific survival: 100
                                                                                                                                                                   (SD: 1.1)                                                                                                                                                                                                                                             4/12 (33) in treated area                                                                                                                                                                                                                                                       

  Lindner et al. [@bib0130]                                            Photothermal laser         Focal                                                            Median: 4.2 (range: 2.9--14.8)     3 + 3: 2 (50)\                             NR                                              1 wk                                 RP                                                                                 4/4 (100) with no residual tumor in treated area                     NR                                          NR                             NR                                                  NR                                         NR                               Overall and cancer-specific survival: 100
                                                                                                                                                                                                      4 + 3: 2 (50)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Raz et al. [@bib0135]                                                Photothermal laser         Focal                                                            Median: 3.76 (range: 2.74--4.79)   3 + 3: 2 (100)                             Low: 2 (100)                                    ≤1 mo                                NR                                                                                 NR                                                                   NR                                          NR                             NR                                                  0/2 (0)                                    NR                               Overall and cancer-specific survival: 100

  Truesdale et al. [@bib0140]                                          Cryoablation               Hemiablation                                                     Mean: 6.54 (SD: 4.87)              ≤6: 50 (65)\                               Low: 44 (57)\                                   Median: 24 mo (0--87)                TRUS 12-core biopsy (for cause)                                                    Only patients having biopsy: 10/22 (45.5)\                           NR                                          72.7                           Mean: 1.23 (SD: 1.38)                               NR                                         NR                               Overall and cancer-specific survival: 100
                                                                                                                                                                                                      7: 25 (32)\                                Intermediate: 31 (40)\                                                                                                                                                  3/22 (14) in treated area\                                                                                                                                                                                                                                                      
                                                                                                                                                                                                      8: 2 (3)                                   High: 2 (3)                                                                                                                                                             All patients:\                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                         10/77 (13); 3/77 (3.9) in treated area                                                                                                                                                                                                                                          

  El Fegoun et al. [@bib0145]                                          HIFU                       Hemiablation                                                     Mean: 7.3 (range: 2.6--10)         ≤3 + 3: 10 (83)\                           NR                                              Median: 10.6 yr (range: 7.5--11.1)   TRUS sextant (protocol)                                                            1/12 (8)                                                             0/12                                        5 yr: 90\                      Median: 1.5 (range: 0.1--6.8)                       1/12 (8) redo HIFU\                        0/12 (0)                         Overall survival: 83\
                                                                                                                                                                                                      3 + 4: 2 (17)                                                                                                                                                                                                                                                                                                                       10 yr: 38                                                                          4/12 (33) ADT                                                               Cancer-specific survival: 100

  Ahmed et al. [@bib0150]                                              HIFU                       Hemiablation                                                     Median: 7.3 (range: 3.4--11.8)     NR                                         Low: 5 (25) Intermediate: 15 (75)               12 mo                                TRUS biopsy of the treated side (protocol)                                         2/19 (11)                                                            0/19                                        NR                             12-mo mean: 1.5 (SD: 1.3)                           1/20 (5) redo HIFU                         0/19 (0)                         Overall and cancer-specific survival: 100

  Ward et al. [@bib0155]                                               Cryoablation               NR                                                               1149 (99%) available\              1148 (99) available\                       1157 (99) available\                            Mean: 21.1 mo (SD: 19.7)\            NR\                                                                                Only patients having biopsy: 43/163 (26.3)\                          NR                                          3 yr: 75.7                     NR                                                  NR                                         NR                               NR
                                                                                                                                                                   \<4: 211 (18%)\                    ≤6: 844 (74)\                              Low: 541 (47)\                                                                                                                                                          All patients:\                                                                                                                                                                                                                                                                  
                                                                                                                                                                   4 to \<10: 782 (68%)\              7: 240 (21)\                               Intermediate: 473 (41)\                                                                                                                                                 43/1160 (3.7)                                                                                                                                                                                                                                                                   
                                                                                                                                                                   10 to \<20: 126 (11%)\             ≥8: 64 (5)                                 High: 143 (12)                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                   \>20: 30 (3%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Tay et al. [@bib0160]                                                MRI-guided HIFU            Uni- or multifocal                                               NR                                 NR                                         NR                                              NR                                   NR                                                                                 0/1                                                                  NR                                          NR                             NR                                                  NR                                         NR                               NR

  Chopra et al. [@bib0165]                                             MRI-guided HIFU            Peripheral zone                                                  Mean: 6.2 (range: 2.7--13.1)       3 + 3: 2 (25)\                             NR                                              \<2 h                                RP                                                                                 8/8 (100)                                                            6/8 (75)                                    NR                             NR                                                  NR                                         0/8 (0)                          Overall and cancer-specific survival: 100
                                                                                                                                                                                                      3 + 4: 4 (50)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                      4 + 3: 2 (25)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Bahn et al. [@bib0170][\*\*](#tblfn0015){ref-type="table-fn"}        Cryoablation               Hemiablation                                                     Median: 5.4 (range: 0.01--20)      3 + 3: 30 (41)\                            Low: 24 (33) Intermediate: 49 (67)              Median: 3.7 yr (range: 1--8.5)       TRUS sextant plus target biopsy of suspicious areas (protocol)                     12/48 (25)\                                                          5/48 (10)\                                  NR                             36-mo mean: 2.1 (SD: 3.8)                           2/73 (3) redo cryoablation\                0/48 (0)                         Overall and cancer-specific survival: 100
                                                                                                                                                                                                      3 + 4: 25 (34)\                                                                                                                                                                                                    11 positive biopsy results in untreated side; 1 treated side                                                                                                                                        1/73 (1.4) brachytherapy, 1/73 (1.4) ADT                                    
                                                                                                                                                                                                      4 + 3: 18 (25)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Ahmed et al. [@bib0175]                                              HIFU                       Unilateral, bilateral or midline ablation                        Median: 6.6 (range: 5.4--7.7)      3 + 3: 13 (32)\                            Low: 11 (27)\                                   12 mo                                TRUS biopsy of treated area (protocol)                                             9/39 (23)                                                            3/39 (8)                                    NR                             Median: 1.9 (IQR: 0.8--3.3)                         4/41 (10) redo HIFU                        0/39 (0)                         Overall survival: 97.7\
                                                                                                                                                                                                      3 + 4: 24 (59)\                            Intermediate: 26 (63)\                                                                                                                                                                                                                                                                                                                                                                                                                                  Cancer-specific survival: 100
                                                                                                                                                                                                      4 + 3: 4 (10)                              High: 4 (10)                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Dickinson et al. [@bib0180][\*\*](#tblfn0015){ref-type="table-fn"}   HIFU                       Hemiablation, unifocal or multifocal                             NR                                 3 + 3: 31 (35)\                            NR                                              Median: 32 mo (range: 24--69)        TRUS biopsy of treated area (protocol)                                             20/72 (28)                                                           10/72 (14)                                  Phoenix 71/87 (82)\            NR                                                  NR/87 (20) redo HIFU\                      NR                               NR
                                                                                                                                                                                                      3 + 4: 50 (57)\                                                                                                                                                                                                                                                                                                                     Stuttgart 57/87 (66)\                                                              4/87 (5) salvage EBRT                                                       
                                                                                                                                                                                                      4 + 3: 7 (8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Nguyen et al. [@bib0185]                                             MRI-guided brachytherapy   Peripheral zone                                                  Median: 5.0\                       3 + 3: 280 (88)\                           Low: 265 (83)\                                  5.1 yr (IQR: 2.8--7.3)               TRUS 12-core biopsy (for cause)                                                    Only patients having biopsy:\                                        NR                                          Phoenix:\                      NR                                                  NR                                         1/318 (0.3)                      Overall and cancer-specific survival: 99.7
                                                                                                                                                                   (IQR: 3.8--6.9)                    3 + 4: 38 (12)                             Intermediate: 53 (17)                                                                                                                                                   17/24 (71)\                                                                                                      5 yr: 91.5\                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                         All patients:\                                                                                                   8 yr: 78.1\                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                         17/318 (5.3)                                                                                                     Phoenix and PSAV: \>0.75/yr\                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          5 yr: 91.9\                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          8 yr: 86.2                                                                                                                                                     

  Napoli et al. [@bib0190]                                             MRI-guided HIFU            Focal                                                            Median: 8.8                        3 + 3: 3 (60)\                             NR                                              Mean: 9 mo (range: 7--14)            RP                                                                                 5/5 (100)                                                            NR                                          NR                             NR                                                  NR                                         NR                               NR
                                                                                                                                                                                                      3 + 4: 2 (40)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Barret et al. [@bib0195]                                             HIFU: 21 (20)\             Hemiablation                                                     Mean: 6.1 (IQR: 5--8.1)            3 + 3: 106 (100)                           Low: 106 (100)                                  Median: 9 mo (range: 6--15)          NR                                                                                 NR                                                                   NR                                          NR                             12-mo median: 2.7 (IQR: 1--4.4)                     NR                                         NR                               NR
                                                                       Brachytherapy: 12 (11)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                       Cryoablation: 50 (47)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                       PDT: 23 (22)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PSA = prostate-specific antigen; NCCN = National Comprehensive Cancer Network; bDFS = biochemical disease-free survival; HIFU = high intensity focused ultrasound; TRUS = transrectal ultrasound; NR = not reported; RP = radical prostatectomy; RITA = radiofrequency interstitial tumor ablation; PDT = photodynamic therapy; EBRT = external beam radiotherapy; SD = standard deviation; IQR = interquartile range; ADT = androgen-deprivation therapy; MRI = magnetic resonance imaging; PSAV = prostate-specific antigen velocity.

At last follow-up unless otherwise stated.

This series partially overlaps with one previously reported.

###### 

Actual population studied in each salvage series with the histologic, biochemical, and cancer long-term outcomes

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                     Technology                 Type of ablation                                 PSA level, ng/ml                  Gleason score at preoperative biopsy (%)   Risk classification (D'Amico or NCCN)   Follow-up, mo, median no. (range)   Postfocal histology (reason)                                             Presence of any cancer                                Presence of clinically significant cancer, actual (%)   bDFS, %         PSA kinetics (at last follow-up unless otherwise stated)        Secondary treatment, actual (%)   Metastatic disease, actual (%)   Mortality, %
  ----------------------------- -------------------------- ------------------------------------------------ --------------------------------- ------------------------------------------ --------------------------------------- ----------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------- --------------- --------------------------------------------------------------- --------------------------------- -------------------------------- -------------------------------------------
  Shariat et al. [@bib0200]     RITA                       Focal                                            Median: 5.7 (range: 0.66--10.8)   Median: 7; range: 6--8                     NA                                      20 (3--38)                          TRUS 12-core biopsy (protocol)                                           At 12 mo: 3/6 (50), 2/6 (33) in the treated area      NR                                                      NR              90% experienced a decrease in PSA \>50% (discrete values: NR)   NR                                NR                               Overall and cancer-specific survival: 100

  Nguyen et al. [@bib0205]      MRI-guided brachytherapy   Peripheral zone                                  Median: 5.5 (range: 1.4--11.6)    2+3: 1 (4)\                                NA                                      47 (14--75)                         NR                                                                       NR                                                    NR                                                      4 yr: 70        NR                                                              NR                                NR                               NR
                                                                                                                                              3+3: 18 (72)\                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                              3+4: 6 (24)                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Eisenberg et al. [@bib0210]   Cryoablation               Hemiablation                                     Median: 3.3 (range: 0.28--8.96)   NR                                         NA                                      18 (6--33)                          TRUS biopsy (protocol)                                                   At 12 mo: 1/10 (10) overall and in the treated area   NR                                                      ASTRO\          NR                                                              NR                                3/15 (20)                        NR
                                                                                                                                                                                                                                                                                                                                                                                                                                                            1 yr: 89\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                            2 yr: 67\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                            3 yr: 50\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                            Phoenix\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                            1 yr: 89\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                            2 yr: 79\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                            3 yr: 79                                                                                                                                           

  Ahmed et al. [@bib0215]       HIFU                       Hemiablation (*n* = 16) or quadrant (*n* = 23)   Median: 3.3 (range: 0.02--27.9)   Unknown: 1 (3)\                            NA                                      17 (10--29)                         Transperineal template biopsy (for cause)                                Only patients having biopsy:\                         NR                                                      2 yr:\          Median: 0.57 (IQR: 0.1--2.3)                                    16/39 (41) had ADT                2/39 (5)                         NR
                                                                                                                                              6: 2 (5)\                                                                                                                                                                                       4/9 (44)\                                                                                                     Phoenix: 49\                                                                                                                                       
                                                                                                                                              7: 32 (82)\                                                                                                                                                                                     All patients:\                                                                                                Stuttgart: 42                                                                                                                                      
                                                                                                                                              ≥8: −4 (10)                                                                                                                                                                                     4/39 (10)                                                                                                                                                                                                                                                        

  Abreu et al. [@bib0220]       Cryoablation               Hemiablation                                     Median: 2.8 (range: 0--8.2)       ≤3 + 3: 5 (20)\                            NA                                      31 (4--90)                          TRUS sextant plus mapping target biopsy of suspicious areas (protocol)   2/25 (8)                                              2/25 (8)                                                5 yr: 54        At 36 mo: mean: 1.2 (SD: 1.6)                                   2/25 (8)                          No                               Overall and cancer-specific survival: 100
                                                                                                                                              3 + 4: 6 (24)\                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                              4 + 3: 8 (32)\                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                              4 + 4: 6 (24)                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PSA = prostate-specific antigen; NCCN = National Comprehensive Cancer Network; bDFS = biochemical disease-free survival; RITA = radiofrequency interstitial tumour ablation; NA = not applicable; NR = not reported; TRUS = transrectal ultrasound; MRI = magnetic resonance imaging; ASTRO = American Society for Therapeutic Radiology and Oncology; HIFU = high-intensity focused ultrasound.

###### 

Perioperative and functional outcome of patients undergoing focal therapy in the primary setting

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                         Length of stay, d, median   Anaesthesia         Complications, actual (%)                        Urinary continence, actual (%)   Erectile function[\*](#tblfn0020){ref-type="table-fn"}, actual (%)                  Rectal toxicity, actual (%)                       Quality of life                                                        Trifecta outcome[\*\*](#tblfn0025){ref-type="table-fn"}, actual (%)
  ----------------------------------------------------------------- --------------------------- ------------------- ------------------------------------------------ -------------------------------- ----------------------------------------------------------------------------------- ------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------
  Madersbacher et al. [@bib0075]                                    NR                          General             NR                                               NR                               NR                                                                                  NR                                                NR                                                                     NR

  Zlotta et al. [@bib0080]                                          NR                          General or spinal   NR                                               NR                               NR                                                                                  NR                                                NR                                                                     NR

  Beerlage et al. [@bib0085]                                        2                           General or spinal   NR                                               NR                               NR                                                                                  Rectourethral fistula: 0/14 (0)\                  NR                                                                     NR
                                                                                                                                                                                                                                                                                          Perineal pain: 14/14 (100)\                                                                                              
                                                                                                                                                                                                                                                                                          Rectal bleeding: NR\                                                                                                     
                                                                                                                                                                                                                                                                                          Diarrhoea: NR\                                                                                                           
                                                                                                                                                                                                                                                                                          PROM: NR                                                                                                                 

  Souchon et al. [@bib0090]                                         NR                          NR                  NR                                               NR                               NR                                                                                  NR                                                NR                                                                     NR

  Moore et al. [@bib0095]                                           1                           General             Urinary retention: 1/6 (17)\                     Pad free: NR\                    1/3 (33)\                                                                           Rectourethral fistula: 0/3 (0)\                   NR                                                                     NR
                                                                                                                    Urethral stricture: NR\                          Leak free: 5/6 (83)\             PROM: Brief Sexual Function Inventory                                               Perineal pain: NR\                                                                                                       
                                                                                                                    UTI: 1/6 (17)\                                   PROM: AUA-7                                                                                                          Rectal bleeding: 2/6 (33)\                                                                                               
                                                                                                                    Outcome measure: NR                                                                                                                                                   Diarrhoea: 2/6 (33)\                                                                                                     
                                                                                                                                                                                                                                                                                          PROM: NR                                                                                                                 

  Bahn et al. [@bib0100]                                            NR                          NR                  NR                                               Pad free: 28/28 (100)\           24/27 (88.8)\                                                                       NR                                                NR                                                                     NR
                                                                                                                                                                     Leak free: NR\                   PROM: Brief Male Sexual Function Index                                                                                                                                                                       
                                                                                                                                                                     PROM: NR                                                                                                                                                                                                                                      

  Onik et al. [@bib0105]                                            NR                          NR                  NR                                               Pad free: 24/25 (96)\            44/51 (85)\                                                                         NR                                                NR                                                                     NR
                                                                                                                                                                     Leak free: NR\                   PROM: NR                                                                                                                                                                                                     
                                                                                                                                                                     PROM: NR                                                                                                                                                                                                                                      

  Ellis et al. [@bib0110]                                           1                           NR                  NR                                               Pad free: 55/55 (100)\           24/34 (70.6)\                                                                       Rectourethral fistula: 0/34 (0)\                  NR                                                                     NR
                                                                                                                                                                     Leak free: 53/55 (96.4)\         PROM: NR\                                                                           Perineal pain: NR\                                                                                                       
                                                                                                                                                                     PROM: NR                         (vacuum therapy and oral therapy for erectile dysfunction offered preoperatively)   Rectal bleeding: NR\                                                                                                     
                                                                                                                                                                                                                                                                                          Diarrhoea: NR\                                                                                                           
                                                                                                                                                                                                                                                                                          PROM: NR                                                                                                                 

  Muto et al. [@bib0115]                                            1                           NR                  Urinary retention: NR\                           Pad free: NR\                    NR                                                                                  NR                                                NR                                                                     NR
                                                                                                                    Urethral stricture 1/25 (4)\                     Leak free: NR\                                                                                                                                                                                                                                
                                                                                                                    UTI 1/25(4)\                                     PROM: UCLA-EPIC, IPSS                                                                                                                                                                                                                         
                                                                                                                    Outcome measure: NR                                                                                                                                                                                                                                                                            

  Murat et al. [@bib0120]                                           NR                          NR                  NR                                               NR                               28/52 (54)\                                                                         NR                                                NR                                                                     NR
                                                                                                                                                                                                      PROM: IIEF-5                                                                                                                                                                                                 

  Lindner et al. [@bib0125]                                         1                           General             Urinary retention: 0/12 (0)\                     Pad free: 12/12 (100)\           NR (100)\                                                                           Rectourethral fistula: 0/12 (0)\                  NR                                                                     6/12 (50)
                                                                                                                    Urethral stricture: 0/12 (0)\                    Leak free: 12/12 (100)\          PROM: IIEF-5                                                                        Perineal pain: 3/12 (25)\                                                                                                
                                                                                                                    UTI: 0/12 (0)\                                   PROM: IPSS                                                                                                           Rectal bleeding: 0/12 (0)\                                                                                               
                                                                                                                    Outcome measure: NR                                                                                                                                                   Diarrhoea: 0/12 (0)\                                                                                                     
                                                                                                                                                                                                                                                                                          PROM: NR                                                                                                                 

  Lindner et al. [@bib0130]                                         NR                          NR                  NR                                               NR                               NR                                                                                  NR                                                NR                                                                     NR

  Raz et al. [@bib0135]                                             1                           General             NR                                               NR                               NR                                                                                  NR                                                NR                                                                     NR

  Truesdale et al. [@bib0140]                                       1                           General or spinal   NR                                               Pad free: 77/77 (100)\           NR\                                                                                 NR                                                NR                                                                     NR
                                                                                                                                                                     Leak free: NR\                   PROM: IIEF                                                                                                                                                                                                   
                                                                                                                                                                     PROM: IPSS                                                                                                                                                                                                                                    

  El Fegoun et al. [@bib0145]                                       NR                          NR                  Urinary retention: 1/12 (8)\                     Pad free: 12/12 (100)\           NR                                                                                  NR                                                NR                                                                     NR
                                                                                                                    Urinary stricture: 0/12 (0)\                     Leak free: NR\                                                                                                                                                                                                                                
                                                                                                                    UTI: 2/12 (16)\                                  PROM: IPSS                                                                                                                                                                                                                                    
                                                                                                                    Outcome measure: NR                                                                                                                                                                                                                                                                            

  Ahmed et al. [@bib0150]                                           1 day                       General             Urinary retention: 0/20 (0)\                     Pad free: 19/20 (95)\            19/20 (95)\                                                                         Rectourethral fistula: 0/20 (0)\                  No significant difference between baseline and last follow-up\         17/19 (89)
                                                                                                                    Urinary stricture: 1/20 (5)\                     Leak free: 18/20 (90)\           PROM: IIEF-15                                                                       Perineal pain: NR\                                PROM: FACT-P, FACT-G                                                   
                                                                                                                    UTI: 0/20 (05)\                                  PROM: UCLA-EPIC, IPSS                                                                                                Rectal bleeding: NR\                                                                                                     
                                                                                                                    Outcome measure: NR                                                                                                                                                   Diarrhoea: NR\                                                                                                           
                                                                                                                                                                                                                                                                                          PROM: FACT-P                                                                                                             

  Ward et al. [@bib0155]                                            NR                          NR                  Urinary retention: 6/518 (1.1)\                  Pad free: 499/507 (98.4)\        169/291 (58.1)\                                                                     Rectourethral fistula: 1/507 (0.1)\               NR                                                                     NR
                                                                                                                    Urinary stricture: NR\                           Leak free: NR\                   PROM: NR                                                                            Perineal pain: NR\                                                                                                       
                                                                                                                    UTI: NR\                                         PROM: NR                                                                                                             Rectal bleeding: NR\                                                                                                     
                                                                                                                    Outcome measure: NR                                                                                                                                                   Diarrhoea: NR\                                                                                                           
                                                                                                                                                                                                                                                                                          PROM: NR                                                                                                                 

  Tay et al. [@bib0160]                                             NR                          NR                  NR                                               NR                               NR                                                                                  NR                                                NR                                                                     NR

  Chopra et al. [@bib0165]                                          NR                          Spinal              NR                                               NR                               NR                                                                                  NR                                                NR                                                                     NR

  Bahn et al. [@bib0170][†](#tblfn0030){ref-type="table-fn"}        1                           NR                  NR                                               Pad free: 73/73 (100)\           36/42 (86)\                                                                         Rectourethral fistula: 0/73 (0)\                  NR                                                                     NR
                                                                                                                                                                     Leak free: NR\                   PROM: IIEF-5                                                                        Perineal pain: NR\                                                                                                       
                                                                                                                                                                     PROM: NR                                                                                                             Rectal bleeding: NR\                                                                                                     
                                                                                                                                                                                                                                                                                          Diarrhoea: NR\                                                                                                           
                                                                                                                                                                                                                                                                                          PROM: NR                                                                                                                 

  Ahmed et al. [@bib0175]                                           1                           General             Urinary retention: 1/41 (2.4)\                   Pad free: 40/40 (100)\           31/35 (86)\                                                                         Rectourethral fistula: suspicion in 1/41 (2.4)\   Significant small deterioration between baseline and last follow-up\   26/31 (84)
                                                                                                                    Urethral stricture: 0/41 (0)\                    Leak free: 39/39 (100)\          PROM: IIEF-15                                                                       Perineal pain: NR\                                PROM: FACT-P, FACT-G                                                   
                                                                                                                    UTI: 0/41 (0)\                                   PROM: UCLA-EPIC, IPSS                                                                                                Rectal bleeding: NR\                                                                                                     
                                                                                                                    Outcome measure: NR                                                                                                                                                   Diarrhoea: NR\                                                                                                           
                                                                                                                                                                                                                                                                                          PROM: NR                                                                                                                 

  Dickinson et al. [@bib0180][†](#tblfn0030){ref-type="table-fn"}   1                           General             NR                                               Pad free: 86/87 (99)\            76/85 (89)\                                                                         Rectourethral fistula: 1/88 (1)\                  Significant deterioration between baseline and last follow-up\         NR
                                                                                                                                                                     Leak free: 56/66 (85)\           PROM: IIEF-15                                                                       Perineal pain: NR\                                PROM: FACT-P                                                           
                                                                                                                                                                     PROM: IPSS, UCLA-EPIC                                                                                                Rectal bleeding: NR\                                                                                                     
                                                                                                                                                                                                                                                                                          Diarrhoea: NR\                                                                                                           
                                                                                                                                                                                                                                                                                          PROM: NR                                                                                                                 

  Nguyen et al. [@bib0185]                                          1                           General             NR                                               NR                               NR                                                                                  NR                                                NR                                                                     NR

  Napoli et al. [@bib0190]                                          1                           NR                  NR                                               NR                               NR                                                                                  NR                                                NR                                                                     NR

  Barret et al. [@bib0195]                                          1--2                        NR                  Urinary retention: 9/106 (8)\                    Pad free: 106/106 (100)\         NR\                                                                                 Rectourethral fistula: 1/106 (1)\                 NR                                                                     NR
                                                                                                                    Urethral stricture: 1/106 (1)\                   Leak free: NR\                   PROM: IIEF-5                                                                        Perineal pain: 1/106 (1)\                                                                                                
                                                                                                                    UTI: 0/106 (0)\                                  PROM: IPSS                                                                                                           Rectal bleeding: 0\                                                                                                      
                                                                                                                    Outcome measure: Clavien-Dindo classification\                                                                                                                        Diarrhoea: NR\                                                                                                           
                                                                                                                    (13% complication rate, 2% major)                                                                                                                                     PROM: NR                                                                                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR = not reported; PROM = patient-reported outcome measure; UTI = urinary tract infection; AUA-7 = American Urological Association symptom index 7; UCLA-EPIC = University of California, Los Angeles-Expanded Prostate Cancer Index Composite; IPSS = International Prostate Symptom Score; IIEF = International Index of Erectile Function; FACT-P = Functional Assessment of Cancer Therapy-Prostate; FACT-G = Functional Assessment of Cancer Therapy-General.

Ability to have penetrative intercourse.

Pad-free, leak-free continence; erections sufficient for penetration; absence of clinically significant disease after focal therapy.

This series partially overlaps with one previously reported.

###### 

Perioperative and functional outcome of patients undergoing focal therapy after radiotherapy failure

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                     Length of stay, d, median   Anaesthesia         Complications, actual (%)                                                          Urinary continence, actual (%)   Erectile function[\*](#tblfn0035){ref-type="table-fn"}, actual (%)   Rectal toxicity, actual (%)                  Quality of life                                       Trifecta outcome[\*\*](#tblfn0040){ref-type="table-fn"}
  ----------------------------- --------------------------- ------------------- ---------------------------------------------------------------------------------- -------------------------------- -------------------------------------------------------------------- -------------------------------------------- ----------------------------------------------------- ---------------------------------------------------------
  Shariat et al. [@bib0200]     1                           Sedation            NR                                                                                 Pad free: NR\                    NR                                                                   NR                                           Difference between baseline and last follow-up: No\   NR
                                                                                                                                                                   Leak free: NR\                                                                                                                                     PROM: Quality of Life Index                           
                                                                                                                                                                   PROM: IPSS                                                                                                                                                                                               

  Nguyen et al. [@bib0205]      1                           General             Urinary retention: NR\                                                             Pad free: 22/25 (88%)\           NR                                                                   Rectourethral fistula: 3/25 (12)\            NR                                                    NR
                                                                                Urethral stricture: 1/25 (4)\                                                      Leak free: NR\                                                                                        Perineal pain: NR\                                                                                 
                                                                                UTI: NR\                                                                           PROM: NR                                                                                              Rectal bleeding: 2/25 (8)\                                                                         
                                                                                Outcome measure: RTOG                                                                                                                                                                    Diarrhoea: NR\                                                                                     
                                                                                                                                                                                                                                                                         PROM: RTOG                                                                                         

  Eisenberg et al. [@bib0210]   NR                          General or spinal   Urinary retention: 0/15 (0)\                                                       Pad free: 14/15 (93.3)\          Ability to have penetrative sex: 2/5 (40)\                           Rectourethral fistula: suspicion 1/15 (7)\   NR                                                    NR
                                                                                Urethral stricture: 1/15 (7)\                                                      Leak free: NR\                   PROM: Sexual Health Inventory for Men                                Perineal pain: 1/15 (7)\                                                                           
                                                                                UTI: NR\                                                                           PROM: NR\                                                                                             Rectal bleeding: NR\                                                                               
                                                                                Outcome measure: NR                                                                                                                                                                      Diarrhoea: NR\                                                                                     
                                                                                                                                                                                                                                                                         PROM: NR                                                                                           

  Ahmed et al. [@bib0215]       1                           General             Urinary retention: NR\                                                             Pad free: 34/39 (87.2)\          Ability to have penetrative sex: NR\                                 Rectourethral fistula: 1/39 (2.6)\           NR                                                    NR
                                                                                Urethral stricture: 1/39 (3)\                                                      Leak free: 25/39 (64.1)\         PROM: IIEF-15                                                        Perineal pain: NR\                                                                                 
                                                                                UTI: 3/39 (8)\                                                                     PROM: UCLA-EPIC, IPSS                                                                                 Rectal bleeding: NR\                                                                               
                                                                                Outcome measure: Clavien-Dindo grade; 1: 3 (8), 2: 0, 3a: 1 (3), 3b: 9 (23), 4:0                                                                                                         Diarrhoea: NR\                                                                                     
                                                                                                                                                                                                                                                                         PROM: NR                                                                                           

  Abreu et al. [@bib0220]       1                           NR                  NR                                                                                 Pad free: 25/25 (100)\           Ability to have penetrative sex: 2/7 (29)\                           Rectourethral fistula: 0/25\                 NR                                                    NR
                                                                                                                                                                   Leak free: NR\                   PROM: IIEF-5                                                         Perineal pain: NR\                                                                                 
                                                                                                                                                                   PROM: NR                                                                                              Rectal bleeding: NR\                                                                               
                                                                                                                                                                                                                                                                         Diarrhoea: NR\                                                                                     
                                                                                                                                                                                                                                                                         PROM: NR                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR = not reported; PROM = patient-reported outcome measure; IPSS = International Prostate Symptom Score; RTOG = Radiation Therapy Oncology Group; UTI = urinary tract infection; UCLA-EPIC = University of California, Los Angeles-Expanded Prostate Index Composite.

Ability to have penetrative intercourse.

Pad-free, leak-free continence; erections sufficient for penetration; absence of clinically significant disease after focal therapy.

[^1]: Joint first authors.
